273 related articles for article (PubMed ID: 27825983)
1. Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening.
O'Duibhir E; Carragher NO; Pollard SM
Mol Cell Neurosci; 2017 Apr; 80():198-207. PubMed ID: 27825983
[TBL] [Abstract][Full Text] [Related]
2. Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b.
El Fatimy R; Subramanian S; Uhlmann EJ; Krichevsky AM
Mol Ther; 2017 Feb; 25(2):368-378. PubMed ID: 28153089
[TBL] [Abstract][Full Text] [Related]
3. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery.
Ahmad G; Amiji M
Drug Discov Today; 2018 Mar; 23(3):519-533. PubMed ID: 29326075
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
5. Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.
Al-Sammarraie N; Ray SK
Cells; 2021 Sep; 10(9):. PubMed ID: 34571991
[TBL] [Abstract][Full Text] [Related]
6. Experimental models and tools to tackle glioblastoma.
Robertson FL; Marqués-Torrejón MA; Morrison GM; Pollard SM
Dis Model Mech; 2019 Sep; 12(9):. PubMed ID: 31519690
[TBL] [Abstract][Full Text] [Related]
7. Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.
MacLeod G; Bozek DA; Rajakulendran N; Monteiro V; Ahmadi M; Steinhart Z; Kushida MM; Yu H; Coutinho FJ; Cavalli FMG; Restall I; Hao X; Hart T; Luchman HA; Weiss S; Dirks PB; Angers S
Cell Rep; 2019 Apr; 27(3):971-986.e9. PubMed ID: 30995489
[TBL] [Abstract][Full Text] [Related]
8. Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells.
Lee CM; Zhu H; Davis TH; Deshmukh H; Bao G
Methods Mol Biol; 2017; 1498():3-21. PubMed ID: 27709565
[TBL] [Abstract][Full Text] [Related]
9. Generation of Isogenic Human iPS Cell Line Precisely Corrected by Genome Editing Using the CRISPR/Cas9 System.
Grobarczyk B; Franco B; Hanon K; Malgrange B
Stem Cell Rev Rep; 2015 Oct; 11(5):774-87. PubMed ID: 26059412
[TBL] [Abstract][Full Text] [Related]
10. CRISPR Del/Rei: a simple, flexible, and efficient pipeline for scarless genome editing.
Feuer KL; Wahbeh MH; Yovo C; Rabie E; Lam AN; Abdollahi S; Young LJ; Rike B; Umamageswaran A; Avramopoulos D
Sci Rep; 2022 Jul; 12(1):11928. PubMed ID: 35831384
[TBL] [Abstract][Full Text] [Related]
11. Applications of CRISPR genome editing technology in drug target identification and validation.
Lu Q; Livi GP; Modha S; Yusa K; Macarrón R; Dow DJ
Expert Opin Drug Discov; 2017 Jun; 12(6):541-552. PubMed ID: 28388235
[TBL] [Abstract][Full Text] [Related]
12. Genome Editing Using Cas9 Ribonucleoprotein Is Effective for Introducing
Hamada T; Yokoyama S; Akahane T; Matsuo K; Tanimoto A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613947
[TBL] [Abstract][Full Text] [Related]
13. CRISPR Genome Engineering for Human Pluripotent Stem Cell Research.
Chaterji S; Ahn EH; Kim DH
Theranostics; 2017; 7(18):4445-4469. PubMed ID: 29158838
[TBL] [Abstract][Full Text] [Related]
14. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
Zhang Y; Sastre D; Wang F
Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
[TBL] [Abstract][Full Text] [Related]
16. Genome editing of human pancreatic beta cell models: problems, possibilities and outlook.
Balboa D; Prasad RB; Groop L; Otonkoski T
Diabetologia; 2019 Aug; 62(8):1329-1336. PubMed ID: 31161346
[TBL] [Abstract][Full Text] [Related]
17. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.
Wang D; Prager BC; Gimple RC; Aguilar B; Alizadeh D; Tang H; Lv D; Starr R; Brito A; Wu Q; Kim LJY; Qiu Z; Lin P; Lorenzini MH; Badie B; Forman SJ; Xie Q; Brown CE; Rich JN
Cancer Discov; 2021 May; 11(5):1192-1211. PubMed ID: 33328215
[TBL] [Abstract][Full Text] [Related]
18. Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9.
Yumlu S; Stumm J; Bashir S; Dreyer AK; Lisowski P; Danner E; Kühn R
Methods; 2017 May; 121-122():29-44. PubMed ID: 28522326
[TBL] [Abstract][Full Text] [Related]
19. Editing the genome of hiPSC with CRISPR/Cas9: disease models.
Bassett AR
Mamm Genome; 2017 Aug; 28(7-8):348-364. PubMed ID: 28303292
[TBL] [Abstract][Full Text] [Related]
20. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
